Responses
Clinical/translational cancer immunotherapy
Original research
Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial
Compose a Response to This Article
Other responses
No responses have been published for this article.